Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Protagonist Therapeutics, Inc. (PTGX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
28.42-0.38 (-1.32%)
At close: 04:00PM EST
28.42 0.00 (0.00%)
After hours: 04:01PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close28.80
Open29.28
Bid13.01 x 900
Ask37.87 x 800
Day's Range28.00 - 30.34
52 Week Range12.80 - 50.54
Volume634,977
Avg. Volume620,811
Market Cap1.356B
Beta (5Y Monthly)2.17
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    /C O R R E C T I O N -- Protagonist Therapeutics, Inc./

    Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11 at 2:15 p.m. EST.

  • PR Newswire

    Protagonist Therapeutics Presents Updated Phase 2 Rusfertide Data in Polycythemia Vera (PV) at ASH 2021 Annual Meeting

    Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today presented updated data from two ongoing Phase 2 studies evaluating rusfertide in patients with polycythemia vera (PV), demonstrating its ability to essentially eliminate the need for phlebotomies in patients. Rusfertide also showed rapid and sustained hematocrit control in patients requiring frequent phlebotomies or those having high baseline hematocrit levels (>48%). The data were presented in two oral presentations

  • PR Newswire

    Protagonist Therapeutics to Present at the JMP Securities Hematology and Oncology Summit

    Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at the upcoming JMP Securities Hematology and Oncology Summit taking place virtually on December 6, 2021.

Advertisement
Advertisement